MMR vaccine in the postpartum does not expose seronegative women to untoward effects

Ann Ist Super Sanita. 2017 Apr-Jun;53(2):152-156. doi: 10.4415/ANN_17_02_12.

Abstract

Background: The aim of this study was to assess whether rubella vaccination immediately after delivery could expose seronegative women to specific untoward effects.

Methods: 163 rubella-seronegative women received Measles-Mumps-Rubella (MMR) vaccine in the immediate postpartum period; they were evaluated at one month and at three months thereafter through telephone interviews. As controls, we matched 163 rubella-seropositive women, who might experience similar symptoms for any reason in the same timeframe.

Results: No relevant difference was still observed in the frequency of arthralgia and myalgia at one and three months. Instead, a statistically significant difference in the frequency of cervical lymphadenopathy and cutaneous rash at one month (p = 0.028 and p = 0.005, respectively), was observed between cases and controls. However, no statistical differences were reported at three months for the same symptoms.

Conclusions: Postpartum rubella vaccination with MMR is safe and advisable to avoid congenital rubella syndrome.

MeSH terms

  • Adult
  • Female
  • Humans
  • Measles-Mumps-Rubella Vaccine / adverse effects*
  • Postpartum Period / immunology*
  • Rubella Syndrome, Congenital / prevention & control
  • Vaccination / adverse effects

Substances

  • Measles-Mumps-Rubella Vaccine